Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
Symphogen, a private biopharmaceutical company developing recombinant antibody mixtures, announced today an oral presentation and a poster at the 2013 Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago, IL. Both cover the results of proof-of-concept studies of SYM004, an anti-EGFR monoclonal antibody (mAb) mixture. Symphogen entered the antibody mixture into the clinic in 2010, and subsequently partnered with Merck KGaA, Darmstadt, Germany, in September 2012.
Help employers find you! Check out all the jobs and post your resume.
